InvestSMART

Immuron Limited (ASX:IMC)

ALERT: Price-sensitive ASX Announcement for IMC
Current share price for IMC : $0.034 0.005 (17.24%)+
Announcement
Release
17 Apr 2026 9:30AM
Price at Release
$0.029
Full Release
download
Summary
Immuron Limited, an Australian biopharmaceutical company, reported a 16% increase in global Q3 sales, driven by its Travelan® product. Year-to-date sales in Australia climbed 14%, while Canadian sales surged over 100% in Q3. In the U.S., sales grew slightly due to strategic marketing efforts, despite the Australian dollar's impact. Immuron's growth is attributed to enhanced digital marketing and an expanded in-store presence. The company’s platform technology utilizes bovine-derived polyclonal immunoglobulins to develop treatments for infectious diseases.
Key Points
  • Immuron reported a 16% increase in global Q3 sales to AUD$1.5 million.
  • Year-to-date sales in Australia rose 14% to AUD$4.2 million.
  • Sales in Canada increased by over 100% in Q3 compared to the previous period.
  • U.S. Q3 sales increased by 1% due to various marketing initiatives.
  • Travelan® is a key product contributing to sales growth, targeting traveler’s diarrhea.
  • Marketing strategies included digital and social media promotions and enhancements in-store presence.
  • The strengthening of the Australian dollar impacted sales in the U.S.
  • Immuron’s technology platform is based on polyclonal immunoglobulins from bovine colostrum.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.